Results 221 to 230 of about 3,868,024 (353)

The 340B Program: A Federal Program in Desperate Need of Revision After Two-And-A-Half Decades of Uncertainty [PDF]

, 2019
Fisher, Nicholas C.
core   +1 more source

Global insight into rare disease and orphan drug definitions: a systematic literature review. [PDF]

BMJ Open
Abozaid GM, Kerr K, Alomary H, Al-Omar HA, McKnight A.   +4 more
europepmc   +1 more source

PHP1 ORPHAN DRUGS: DOES SOCIETY VALUE RARITY?

, 2010
Arnold Desser, IS Kristiansen
openalex   +1 more source

Estimating the minimal cost of delivering nutrition‐specific and nutrition‐sensitive interventions in Ethiopia

Maternal &Child Nutrition, EarlyView.
The minimum cost of the 10 years on identified nutrition‐specific and nutrition‐sensitive interventions of the National Food and Nutrition Strategy in Ethiopia is estimated to be US$ 2.55bn with an average annual cost of $250 million over 10 years (2021–2030), which is only 2.3% of the Ethiopian Annual GDP 111.27 billion US dollars in 2021 (World bank).
Yetayesh Maru, Firehiwot Mesfin, Arnaud Laillou, Ramadhani Noor, Shiva Raj Adhikari, Meseret Zelalem, Hiwot Darsene, Solomon Memire, Andarge Abie, Stanley Chitekwe   +9 more
wiley   +1 more source

Towards a sustainable rare disease and orphan drug ecosystem in Saudi Arabia: policy insights from a multi-stakeholder workshop. [PDF]

Front Pharmacol
Abozaid GM, Al-Omar HA, Alrabiah A, AlMuaither A, McKnight AJ.   +4 more
europepmc   +1 more source

Five-Year Sales for Newly Marketed Prescription Drugs With and Without Initial Orphan Drug Act Designation.

JAMA, 2023
Tu SS, Nagar S, Kesselheim AS, Lu Z, Rome BN.   +4 more
europepmc   +1 more source

Successfully Navigating Food and Drug Administration Orphan Drug and Rare Pediatric Disease Designations for AAV9-hPCCA Gene Therapy: The National Institutes of Health Platform Vector Gene Therapy Experience. [PDF]

Hum Gene Ther, 2023
Lomash RM, Shchelochkov O, Chandler RJ, Venditti CP, Pariser AR, Ottinger EA, NIH PaVe-GT Team.   +6 more
europepmc   +1 more source

PHP24 CRITICAL ASSESSMENT OF BELGIAN REIMBURSEMENT DOSSIERS OF ORPHAN DRUGS

, 2010
A. Denis, Lut Mergaert, Christel Fostier, Irina Cleemput, Frank Hulstaert, Steven Simoens   +5 more
openalex   +1 more source

Is orphan drug pricing blowing a bubble? The unique situation of orphan drugs and why high prices will likely persist [PDF]

, 2013
John-Paul Michaud, Robin Modi, M. Ian Phillips   +2 more
openalex   +1 more source

Central mechanisms of emesis: A role for GDF15

Neurogastroenterology &Motility, Volume 37, Issue 3, March 2025.
Abstract Background Nausea and emesis are ubiquitously reported medical conditions and often present as treatment side effects along with polymorbidities contributing to detrimental life‐threatening outcomes, such as poor nutrition, lower quality of life, and unfavorable patient prognosis.
Tito Borner, Allison M. Pataro, Bart C. De Jonghe   +2 more
wiley   +1 more source